TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation. Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s mult ...

TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation. Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s mult ...

Core Insights - Quantum BioPharma Ltd. reported strong financial results for Q3 2025, showcasing significant improvements in shareholder equity and a reduction in liabilities, indicating a robust financial position and operational momentum [2][3][15] Financial Performance - Shareholder equity increased by 275%, rising from US$2 million to US$7.5 million [5] - Total liabilities decreased by 50%, from US$13.2 million to US$6.6 million, primarily due to the elimination of convertible debentures [5][6] - The debt-to-equity ratio improved by 87%, from 6.47x to 0.89x, reflecting a stronger balance sheet [5] - General and Administrative expenses decreased by approximately US$210,000 compared to the same quarter the previous year [6] - The current ratio improved from 0.78x to 1.41x, indicating enhanced liquidity [5] Clinical Development - The company is advancing its multiple sclerosis drug, Lucid-21-302 ("Lucid-MS"), which has shown promise in pre-clinical studies to halt nerve demyelination [4][15] - A joint PET study with Massachusetts General Hospital has commenced, with the first patient scanned to validate a novel imaging technique for monitoring myelin integrity in MS [7][15] - Phase 1 oral toxicity studies of Lucid-MS have been completed, showing no toxicity or side effects [12] Product Development and Market Growth - Unbuzzd Wellness Inc., the licensee of Quantum's unbuzzd product, is preparing for a capital raise of up to US$5 million in anticipation of a possible IPO, with no equity dilution for Quantum shareholders [8][13] - Health Canada granted a Product License for Qlarity, a natural health product, allowing Quantum to sell it in Canada [15] Legal Matters - Quantum has filed a memorandum opposing a motion to dismiss in its lawsuit against CIBC and RBC regarding alleged stock market manipulation [9]

Core Viewpoint - Quantum BioPharma Ltd. is conducting a non-brokered private placement of up to 30 Class A Multiple Voting Shares at a price of $25 per share, aiming for gross proceeds of up to $750 million, primarily to enhance voting rights and for general working capital purposes [1][2]. Group 1: Offering Details - The private placement is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, existing holders of Class A Multiple Voting Shares [1][3]. - If fully subscribed, the voting rights attached to Class A Multiple Voting Shares will increase to 75.27%, nearly restoring the percentage to that at the time of the company's IPO in 2018 [2]. - The board of directors unanimously approved the Offering, excluding Saeed and Durkacz from discussions due to their interests [2]. Group 2: Related Party Transactions - The Offering involves related-party transactions as it is anticipated that Xorax Family Trust and Fortius Research and Trading Corp. will purchase all Class A Multiple Voting Shares issued [3]. - The transaction is expected to be exempt from formal valuation and minority shareholder approval requirements under MI 61-101, as the fair market value will not exceed 25% of the company's market capitalization [3]. Group 3: Shareholder Structure - Prior to a recent transfer, the Transferor and Joint Actors held approximately 50% of the outstanding Class A Multiple Voting Shares and 24.85% of the voting rights attached to all voting securities [7]. - Following the transfer of 77,000 Class B Subordinate Voting Shares, the ownership structure changed, with the Transferor and Joint Actors now holding approximately 23.77% of the voting rights [8]. Group 4: Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at treating multiple sclerosis [12]. - The company retains a 20.10% ownership in Unbuzzd Wellness Inc., which includes a royalty agreement for sales from its product unbuzzd™ [12].

Core Points - Quantum BioPharma Ltd. has announced the expiration of 53,147 warrants, which were part of a previous financing completed on October 20, 2020, marking the end of the last tranche of warrants issued to hedge funds and investment funds [1] - The company has set October 27, 2025, as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares, as part of a plan to deliver litigation-linked CVRs to shareholders [2][3] - Each CVR will allow holders to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds from the company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and seeks damages exceeding USD $700 million [3][4] - The potential payment from the CVRs is contingent upon the company receiving Qualifying Net Proceeds from the litigation, and no payments will be made unless such proceeds are received [4][5] - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in multiple sclerosis [6] - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the sales of unbuzzd™, and has a royalty agreement that provides 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [6]

Core Viewpoint - Quantum BioPharma Ltd. announces the expiration of 53,147 warrants and reiterates the record date for the distribution of contingent value rights (CVRs) to shareholders, linked to ongoing litigation against financial institutions for alleged stock price manipulation [1][2][3]. Group 1: Warrants Expiration - The company has expired 53,147 warrants, which were part of a previous financing completed on October 20, 2020, and represents the last tranche issued to hedge funds and investment funds [1]. - The original number of warrants issued was 3,454,543 before a reverse stock split of 65 to 1 [1]. Group 2: Contingent Value Rights (CVRs) - The record date for the distribution of CVRs is set for October 27, 2025, on a one-for-one basis for holders of Class B Subordinate Voting Shares [2]. - Each CVR will entitle holders to a pro rata portion of a minimum of 10% and up to 50% of the net proceeds from the company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million [3][4]. - Payments under the CVRs will only occur if the company receives net proceeds from the litigation, and there is no guarantee that any proceeds will be received [5][8]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various stages of development [6]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key mechanism in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of health products, and has a royalty agreement that provides 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [6].

Core Viewpoint - Quantum BioPharma Ltd. strongly refutes allegations of securities law violations made by The Schall Law Firm and DJS Law Group, describing the claims as vague and unsubstantiated [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [5]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [5]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5]. Legal Response - The company views the announcements from the law firms as opportunistic litigation tactics aimed at exploiting public markets without merit [3]. - Quantum BioPharma is reviewing the conduct of the law firms involved and plans to take appropriate action to protect its reputation [3]. Call for Information - The company invites individuals or entities who feel they have been treated unfairly by the law firms to come forward, assuring confidentiality [4].

Core Points - Quantum BioPharma Ltd. has announced a public whistleblower policy offering rewards up to USD $7 million for information leading to a trial victory or settlement in its ongoing lawsuit against major financial institutions for stock manipulation [1][3][9] - The lawsuit seeks over USD $700 million in damages due to alleged illegal tactics, including "spoofing," which artificially depressed the company's stock price from approximately USD $460 in early 2020 to less than USD $10 by late 2024 [10][9] - The company emphasizes its commitment to restoring market integrity and holding alleged perpetrators accountable through this initiative [5][12] Whistleblower Policy - The cash reward will be granted if the information significantly contributes to a final judgment or binding settlement [3][4] - Eligible information includes evidence of illegal trading practices, such as spoofing and spreading false information [3][4] - The program does not interfere with existing SEC whistleblower programs, allowing individuals to report directly to the SEC while also participating in Quantum's initiative [6][7] Legal Context - The lawsuit is characterized as one of the largest spoofing cases in decades, with substantial evidence gathered by experienced law firms [10][12] - The company is actively seeking additional evidence and information from individuals who may have knowledge of the alleged manipulation [13][11] - Legal representation is provided on a contingency basis, meaning the company incurs no upfront legal costs [10] Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [14] - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenues [14] - The company is committed to involving its shareholder community in addressing the impacts of stock manipulation [13]

Core Viewpoint - Quantum BioPharma Ltd. has announced the establishment of October 27, 2025, as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares, linking potential future recoveries from ongoing litigation directly to shareholders [1][3]. Group 1: CVR Distribution Details - Each CVR will allow holders to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds recovered from the Company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and seeks damages exceeding USD $700 million [2]. - Payments under the CVRs will only occur if the Company receives net proceeds from the litigation following a settlement or a final, non-appealable judgment, referred to as "Qualifying Net Proceeds" [2][4]. - The distribution date for the CVRs is currently undetermined and contingent upon the Company receiving Qualifying Net Proceeds from the litigation [5]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [6]. - The Company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of the unbuzzd™ product, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% [6]. - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [6].

Core Insights - Quantum BioPharma Ltd. has received two final reports related to its drug candidate Lucid-MS for Multiple Sclerosis, marking a significant milestone in its development process [1][2] - The reports will support the company's Investigational New Drug (IND) application to the US FDA for a Phase 2 clinical trial [1][2] - Lucid-MS is positioned as a first-in-class treatment targeting demyelination in Multiple Sclerosis [2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [3] - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the OTC version of its product unbuzzd™ [3] Financial and Strategic Aspects - The agreement with Unbuzzd Wellness Inc. includes a royalty structure of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% indefinitely [3] - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]